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Biochemical Markers Associated with the
Stages of Promotion and Progression
during Hepatocarcinogenesis in the Rat
by H. C. Pitot,* Y. Dragan,* L. Sargent,* and Y.-H. Xu*
Specific biochemical changes occurring during hepatocarcinogenesis have been sought by many investi-
gators. The development ofmultistage models for hepatocarcinogenesis in the rodent has renewed interest
in such markeralterations in preneoplastic as well as neoplastic hepatocytes. Preneoplastic altered hepatic
foci (AHF) exhibit specific histomorphologic changes as viewed with tinctorial stains and show a variety
of biochemical changes as evidenced by enzyme and immunohistochemistry and by other histochemical
markers. During the reversible stage of promotion when AHF are scored by multiple markers, the distri-
bution ofmarkers within these lesionsdiffers withthe useofdifferentpromotingagents. One interpretation
ofthis finding is that each promoting agent stimulates the replication of a set of initiated cells exhibiting
the phenotypic characteristics of a specific programmed phenotype. The same markers score AHF during
the stage of progression, but many AHF in this stage are phenotypically heterogeneous, exhibiting in
tissue sections a "focus-in-focus" pattern of marker alteration. These latter changes can be correlated
with the appearance ofkaryotypic alterations in preneoplastic hepatocytes. On the other hand, it has been
difficult to demonstrate the activation, either mutational or transcriptional, ofproto-oncogenes until this
stage of progression in rat hepatocarcinogenesis. Thus, a study of biochemical and molecular markers
during the stages of hepatocarcinogenesis may lead to a better understanding of potential mechanisms
involved in the development of neoplasia through the stages of initiation, promotion, and progression.
Introduction
The multistage nature ofneoplastic development has
now been demonstrated during carcinogenesis in num-
erous organs in the mammal (1) as well as in cell culture
(2). While a variety of"intermediate" lesions have been
described in the development of various neoplasms in
both animals and humans (3), one of the best studied
and most easily quantitated experimental multistage
models is seen in rat hepatocarcinogenesis (4).
Prominent among early investigations ofexperimen-
tal carcinogenesis ofthe liver were those of Farber (5),
Goldfarb and Zak(6), and Gossnerand Friedrich-Freksa
(7). In the former two laboratories (5,6), the importance
oflesions known as "regenerating nodules" in the path-
ogenesis ofhepatocellular carcinoma was proposed. The
latter investigators (7), on the other hand, described
focal cellular alterations in hepatocytes characterized
by a deficiency in the histochemical staining of the en-
zyme glucose-6-phosphatase. These investigators, par-
ticularly in a later study (8), suggested that these focal
lesions or "islands" played a role in the development of
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carcinoma or in some instances were themselves the
direct precursors of malignant hepatic lesions. Similar
focal lesions identified by hematoxylin and eosin (H &
E) stains were later described in both rats (9) and mice
(10), although in the latter instance there was no dis-
tinction between benign neoplasia, preneoplasia, and
hyperplasia.
After these earlier studies, other histologic and his-
tochemical characteristics ofsuch islands, or altered he-
patic foci (AHF) as referred to in this text, were de-
scribed. Hori (11) and later Kitagawa (12) described
several histochemical alterationsinfocallesionsinlivers
of rats administered 3'-methyl-4-dimethylaminoben-
zene (3'-MDAB) or 2-acetylaminofluorene (AAF), re-
spectively, in the diet. Later, Bannasch and his asso-
ciates (13,14) described the accumulation orglycogen or
"glycogenosis" in focal lesions of livers of rats admin-
istered several hepatocarcinogens, including thioac-
etamide andnitrosomorpholine. Prominentamongthese
earlier studies were developments resulting from the
observation by Fiala et al. (15) of an increased expres-
sion of the enzyme y-glutamyl transpeptidase in both
mouse and rat hepatomas. Subsequently, Kalengayi et
al. (16) demonstrated the presence of y-glutamyl trans-
peptidase (GGT) activity in focal lesions ofthe livers of
rats administered aflatoxin B1, and other studies (17-
19) confirmed such investigations in both early and latePITOT ET AL.
lesions of hepatocarcinogenesis in the rat. More re-
cently, Satoh et al. (20,21) demonstrated that the pla-
cental form of glutathione S-transferase (PGST) is an
exceptionally efficient immunohistochemical marker for
AHF in rat hepatocarcinogenesis. To date, numerous
morphologic and molecularmarkers forAHF have been
described (22).
Morphologic and Molecular Markers
of Altered Hepatic Foci
Severalhistologic and histochemical characteristics of
AHF were described more than two decades ago (see
above), but in the last 15 years numerous investigations
have markedly expanded these parameters. The reader
is referred to several reviews for a more extensive dis-
cussion of this subject (23-25).
Morphologic Markers
Themorphology ofAHF hasbeen studied extensively
withthe lightmicroscope and standard histologic stains.
One of the first attempts at standardization of the no-
menclature of such lesions with morphologic character-
istics was reported in a 1975 workshop (26), when the
terms "foci of cellular alteration" and "neoplastic nod-
ules" were used to denote lesions here designated as
AHF and as hepatocellular hyperplasia or hepatocel-
lular adenoma in other publications (27). A later panel
developed a technicolor monograph of the morphology
of such lesions (28), and a workshop held in Japan in
1985 (29) also designated the nomenclature ofthese le-
sions in a similar manner.
The detailed histomorphology ofAHF has been stud-
ied extensively by Bannasch and his co-workers (14,30).
Their classification ofAHF, which extends that ofear-
lier proposals (26,29), is descriptive and includes clear-
cell, acidophilic-cell, intermediate-cell, tigroid-cell, ba-
sophilic-cell, and mixed-cell AHF (30). Although most
of these lesions were induced by carcinogenic nitrosa-
mines, several studies have also investigated the
morphology of spontaneous, or background, AHF.
Ward (31) found AHF in livers of 2-year-old Fischer
344 rats used as untreated controls in carcinogen bioas-
says. The morphology ofthese lesions was quite similar
to those ofearlier reports. Recently, Harada et al. (32)
have undertaken a careful quantitative evaluation of
such spontaneous AHF in the same strain of animals.
In their quantitative investigations they demonstrated
thatmostofthese AHF were ofthebasophilicand clear-
cell variety, the former predominantly in females and
the latter predominantly as spontaneous lesions in
males. In a related study (33), these investigators dem-
onstrated that the morphologic characteristics ofchem-
ically induced AHF were significantly different from
those seen in spontaneous AHF.
Biochemical (Molecular) Markers of
Altered Hepatic Foci
The morphologic variations ofAHF and their cellular
populations (see above) are relatively limited compared
with the wide variety ofexpression ofvarious genes in
cells of AHF as monitored by enzyme-, immunohisto-
chemistry, and other histochemical markers. A recent
review (22) has listed many of these markers and is
reproduced in Table 1.
When multiple markers are used to investigate pop-
ulations of AHF within a single liver, in a number of
model systems an extreme degree of molecular (phe-
notypic) heterogeneity of AHF is evident (34-36). On
the other hand, there is some, but not absolute, con-
sistency with respect to specific phenotypic markers
such as those involved in xenobiotic metabolism, in
which a number of cytochrome P-450 isozymes and re-
lated phase I enzymes are decreased within AHF and
in which phase II enzymes of xenobiotic metabolism
such as PGST are increased (37,38). Exceptions to this
generalization exist (38). One of the more ubiquitous
markers that has been described recently is a decrease
in the expression of the gene for the gap junction pro-
tein, connexin 32 (39). Heterogeneity has also been
noted when a number of monoclonal antibodies to he-
patic antigens are used as markers (40).
Stages in Hepatocarcinogenesis
The molecular markers noted in Table 1 have been
used to study the natural history of hepatocarcinoge-
nesis and especially the characteristics of altered he-
patic foci. Numerous models of hepatocarcinogenesis,
both multistage and otherwise, have been developed
(41). In all such models it has been possible to demon-
strate distinctive steps or stages, not all ofwhich have
necessarily been comparable frommodeltomodel. Most
such models agree that the stage ofinitiation results in
the irreversible alteration of individual hepatocytes,
which then, by clonal proliferation, give rise to AHF,
some of the latter developing into hepatocellular car-
cinomas, usually afterexpansionintogross nodules (42-
44). In virtually all models, however, the initial expan-
sion of initiated cell clones is operationally reversible
by withdrawal ofthe promoting stimulus (1). Hendrich
et al. (45) demonstrated this phenomenon in a quanti-
tative manner and also showed that re-administration
ofthe promotingagentcontinues the stage ofpromotion
in the same number ofinitiated clones. The operational
reversibility of the stage of tumor promotion and the
effect ofavariety ofenvironmental factors onthis stage
including age, nutritional status, hormonal environ-
ment, etc., have been demonstrated in a number of
multistage carcinogenesis models (46-48), as well as in
the human (49); this argues strongly that the develop-
mentofthe stage ofpromotionis notdirectlydependent
on the induction of genetic alterations. On the other
hand, the chronic administration of promoting agents
can lead to the development of neoplasia even in the
absence of exogenous initiation (50,51). This effect is
most likely the result of promotion ofendogenously or
fortuitously initiated cells within the host liver (4,52).
It is by such a mechanism that promoting agents are
carcinogenic.
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Table 1. Histochemical reactions of cells of altered hepatic foci
in the rat.a
Histochemical reactions Change
Enzyme histochemistry
Acid phosphatase
Aldehyde dehydrogenase
Alkaline phosphatase
a-Naphthylbutyrate esterase
1-Glucuronidase
Canalicular ATPase
D-T diaphorase
Deoxyribonuclease
5'-Nucleotidase
y-Glutamyltranspeptidase
Glucose 6-phosphatase
Glucose 6-phosphate dehydrogenase
Glyceraldehyde-3-phosphate
dehydrogenase
Nonspecific esterase
Phosphorylase
Ribonuclease
Succinic dehydrogenase
UDP-glucuronyltransferase
Immunohistochemistry
a-Fetoprotein
Albumin (in analbuminemic rats)
Albumin (in normal rats)
c-fos gene product
c-Ha-ras gene product
Connexin 32 (27-kDa gap
junction protein)
Cytochrome P450)
(methylcholanthrene inducible)
Cytochrome P450
(phenobarbital inducible)
Epoxide hydrolase (PN antigen)
y-Glutamyltranspeptidase
Glucose-6-phosphate
dehydrogenase
Glutathione S-transferase
(placental form)
Glutathione S-transferases
(A and B forns)
Glutathione S-transferases
(B and C forms)
NADPH cytochrome P450
reductase
Plasma membrane antigens
Pyruvate kinase (liver form)
Serine dehydratase
Tryptophan oxygenase
Other histochemical markers
Marker (function)
Fibronectin
Glutathione content
Iron deficiency
Lipid peroxidation
Glycogen accumulation
In situ hybridization
Albumin
y-Glutamyltranspeptidase +
a (+) Increased expression of the marker in a significant number
or majority of altered hepatic foci (AHF); (-) decreased expression
of the marker compared with expression in non-AHF hepatocytes;
(±) slight or variable increased and/or decreased expression of the
marker relative to non-AHF hepatocytes. From Pitot (22). See Pitot
(22) for original references ofeach example given in the table.
The final stage of progression, in which malignant
neoplasms, karyotypic abnormalities, and enhanced
proto-oncogene expression occur, canobviouslybeiden-
tified in all models of multistage hepatocarcinogenesis.
The major problem lies in the distinction or boundary
between the stages of promotion and progression (3).
Marker Expression during the Stage
of Promotion
In order to study in a quantitative manner the dis-
tribution ofphenotypic markers ofAHF when multiple
markers are used for analysis, suitable methodologies
are necessary. Campbell et al. (53) developed such a
technique for use with three markers, and recently Xu
et al. (36) have extended this to four markers and po-
tentially even more. Earlier studies by Peraino et al.
(34) had demonstrated that, when as many as six mark-
ers were used, the phenotypic heterogeneity was such
that virtually any ofthe more than 100 combinations of
these markers could be qualitatively identified within
one or more AHF. Using the quantitative technology
described, Xu et al. (36) described the variation in the
distribution offourmarkers in AHF oflivers ofanimals
subjected to an initiation-promotion protocol, with di-
ethylnitrosamine (DEN) as initiator and phenobarbital
(PB) as promoting agent and with age and sex as var-
iables. The distribution ratio of phenotypes in this ex-
periment, based on the "any" category (36,53), may be
seen in Figure 1 for both males and females in animals
that had been initiated and promoted compared with
those that received no initiation with DEN but were
given PB to promote endogenous or fortuitous AHF.
As can be seen, the distributions are significantly dif-
ferent between those focal lesions initiated with DEN,
which includes spontaneous AHF as well, but the latter
are considerablyfewerin numberthanthe former. Fur-
thermore, the distribution changes with age in both
sexes. These quantitative changes argue strongly that
tumor promotion, as exemplified by the development of
AHF in multistage hepatocarcinogenesis, is quite de-
pendent on the environment as well as on the initiating
agent itself, on the assumption that spontaneously ini-
tiated cells that developed into AHF resulted from
agents other than DEN.
An even more dramatic effect can be seen by altering
the promoting agent itself. Promotion with PB or with
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (54) results
in a phenotypic distribution of AHF which is similar
between the two agents. However, when one compares
the phenotypic distribution ofAHF promoted by phen-
obarbital with that resulting from promotion by three
otherstructurallyunrelatedpromotingagents, C.I. Sol-
vent Yellow 14, chlorendic acid, and tamoxifen, signif-
icantly different phenotypic distributions of AHF are
seen (Fig. 2) (55). In this series PB promotes AHF, all
of which can be scored by PGST and GGT (36). Chlo-
rendic acid and C.I. Solvent Yellow 14 promote AHF
that are detected primarily by their increased expres-
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FIGURE 1. Ratios ofindividual phenotypes ofAHF compared with the "any" phenotype in male and female rats as shown after (A) promotion
with phenobarbital or (B) initiation with diethylnitrosamine and promotion with phenobarbital. The marker symbols employed are: S
placental form of glutathione S-transferase; R, y-glutamyl transpeptidase; Y, canalicular ATPase; G, glucose 6-phosphatase; and the
combinations as shown. The reader is referred to the original reference for further details (36).
sion of PGST. GGT is an inefficient marker of AHF
promoted by these agents. This is in contrast to the
finding that both PGST and GGT (56) are inefficient
markers for the class of promoting agents that induce
peroxisomes. The fourth promoting agent used in this
study, tamoxifen, a synthetic anti-estrogen, demon-
strated that glucose 6-phosphatase is the best marker
for AHF promoted by this agent.
These distinctivephenotypic distributions ofAHF re-
sulting from treatment with different promoting agents
may be due to the alteration of expression of specific
genes within the AHF by a specific promoter (57). This
idea has not yet been fully explored, but recent studies
by Yeldandi et al. (58) suggest that the phenotypic
expression induced by promotion with a peroxisorne
proliferator is not altered by replacement of this pro-
moter with 2-acetylaminofluorene.
Alternatively, a promoting agent may stimulate the
proliferation of only the subset of initiated cells that
exhibit a specific programmed phenotype. This pos-
sibility is supported by the finding ofa smaller number
ofAHF resulting from a given dose ofDEN when pro-
moted by agents other than phenobarbital or TCDD
(Fig. 2). In addition, the peroxisome proliferators in-
duce alargenumberofquitesmallAHF scoredbyPGST
and GGTinadditiontolarge AHF andneoplasms scored
by ATPase and G6Pase but not by GGT (59). Although
these studies suggest that a subset ofthe initiated cells
may be expanded by any single promoting agent, more
experimentation is necessary to determine the mecha-
nismofthedifferentialphenotypicdistributionresulting
from various promoting agents.
Markers during the Stage of Progression
Since it is in the stage ofprogression that malignant
neoplasia develops, specific markers for this stage
would, underidealcircumstances, bespecificforcancer.
As yet, no such marker has been developed under any
circumstances orinany system, human oranimal. How-
ever, certain characteristics ofthis stage havebeenten-
tatively developed in multistage hepatocarcinogenesis.
SincenumerousAHF arethefirstmorphologiclesions
seen during the process of multistage hepatocarcino-
genesis in a number ofspecies, and the number ofneo-
plasms produced by an initiation-promotion protocol is
orders ofmagnitude less than the number ofAHF (36),
one would assume that an intermediate lesion of some
sort might be detectable as the immediate precursor of
malignancy. The most obvious morphologic lesion ex-
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FIGURE 2. Phenotypic distribution ofthe number ofAHF in female rats treated with the various compounds as promoting agents for at least
a 6-month period following initiation with diethylnitrosamine. S, placental form ofglutathione S-transferase; R, -y-glutamyl transpeptidase;
Y, canalicular ATPase; G, glucose 6-phosphatase; and the combinations as shown. The reader is referred to the original reference for details
(55).
hibiting such characteristics is the "carcinoma in situ,"
which occurs in the development of a variety ofhuman
and animal organs (3).
In multistage hepatocarcinogenesis, the most obvious
candidate for such an intermediate lesion is the phe-
notypically heterogeneous focus termed a "focus-in-fo-
cus" (60). Such lesions can be induced by the initiation-
promotion-initiation (IPI) protocol, as was first de-
monstrated by Scherer and his colleagues (61). Using
the techniques of quantitative stereology, we have at-
tempted to extend the earlier results ofScherer and his
colleagues through the use ofthe IPI protocol recently
described (62). In studies reported earlier (3), we were
able to show a 2- to 3-fold increase in the numbers of
foci-in-foci induced by the IPI protocol compared with
control animals that were initiated and then promoted
only. However, at best, these studies indicated a qual-
itative difference, much like studies determining
whether one or more malignancies had developed in the
experimental animals. Although the quantitative analy-
sis ofthe total number of AHF could be carried out by
the techniques of quantitative stereology (53), quanti-
tation of foci-in-foci must be performed in two dimen-
sions, since no technique for the three-dimensional
quantitative analysis of such lesions has yet been de-
veloped.
As an alternative, it may be possible to determine
the number ofpromotion-independent AHF as a reflec-
tion of those AHF entering the stage of progression.
Such analyses depend on the reversibility of the stage
of promotion in rat hepatocarcinogenesis, as has been
established (see above). In this experiment the IPI pro-
tocol was employed, but after the second initiation, the
promoting agent, PB, was removed from the diet, and
the animals were maintained on the diet without any
promoting agent. The results of such a study are seen
in Table 2.
As can be seen from Table 3, both ofthe "progressor"
agents employed, ethylnitrosourea and hydroxyurea,
exhibited a significantly larger number of promotion-
independentAHFthandidcontrolanimalsnotreceiving
these compounds. Furthermore, the difference in ef-
fectiveness ofthe two compounds may be reflected in a
dramatic difference in the numbers of promotion-inde-
pendent AHF induced. If one assumes that the control
value may reflect those AHF that are still promoted by
endogenous factors such as estrogens or diet (36), then
ethylnitrosourea appears to be almost an order of mag-
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Table 2. Percentages of GGT+ and GGT- hepatocytes with chromosome damage isolated from rats on
initiation-promotion (Peraino) (34) and initiation-promotion-initiation ( IPI) protocols.a
Chromosomal
Protocol Chromatid Isochromatid Fragments rearrangements
Peraino
GGT+ 4.0 ± 1.0 0.0 0.0 0.0
GGT- 3.0 ± 1.0 0.0 0.0 0.0
IPI
GGT+ 28.0 ± 5.0 16.0 ± 6.0 7.0 ± 2.0 17.0 ± 2.0
GGT- 21.6 ± 2.0 14.0 ± 2.0 16.0 ± 1.0 10.0 ± 5.0
aGGT+ and GGT hepatocytes were isolated from livers ofanimals on the Peraino and IPI protocols (see text for details), and the chromosome
spreads were developed by techniques previously described by Sargent et al. (68).
nitude more effective than hydroxyurea as a progressor
agent. Preliminary studies also indicate that an in-
creased number ofmalignant hepatic neoplasms is seen
in rats 6 to 10 months after the administration ofethyl-
nitrosourea in this protocol.
Karyotypic Changes As Markers of the
Stage of Progression in Rat
Hepatocarcinogenesis
The karyology of hepatocytes during the process of
carcinogenesis in the rat has been studied a number of
times during the past three decades. A relatively early
study by Grundman (63) demonstrated that nuclei of
early basophilic focal lesions contained a diploid amount
of DNA. These findings were basically confirmed with
a similar technology in at least two more recent publi-
cations (64,65). Seglen and his co-workers (66) demon-
strated that both hepatocellularnodules and carcinomas
exhibited similar, predominantly diploid nuclei in the
cells of these lesions. More recently, with techniques
developed in our laboratory (67), Sargent et al. (68)
confirmed the earliermicrospectrophotometric analyses
demonstrating that GGT+ cells isolated from the livers
of rats in the stage of promotion are almost entirely
diploid in nature, as determined by their karyotype.
These studies, confirming earlier investigations by an
entirely different method, argue strongly that the ini-
Table 3. The number of altered hepatic foci resulting from the
application of an initiation-promotion-initiation (IPI) protocol
to adult female rats.a
Treatment Number of AHF/liver
(IPI) (4 markers)
DEN/PB/ENU 18,500 + 1,500
DEN/PB/HU 6,600 + 700
DEN/PB/- 4,900 + 250
aThe IPI protocol and the four markers used in its analysis have
been described previously (36,62). Diethylnitrosamine (DEN) was
administered at a dose of15 mg/kg to 4-day-old Sprague-Dawley rats.
At the time of weaning, female animals were placed on 0.05% phen-
obarbital (PB) for 4 additional months, at which time a single dose of
ethylnitrosourea (ENU) at a dose of 100 mg/kg was administered
intraperitoneally 24 hr after a 70% partial hepatectomy. Similarly,
hydroxyurea (HU) was given at a dose of 100 mg/kg three times at
10-hr intervals beginning 20 hr after a 70% partial hepatectomy. In
the last group only a partial hepatectomy was performed, with no
additional initiation.
tiated cells within the liver are probably diploid as well,
although the predominance of hepatocytes in the adult
rat are tetraploid or of higher ploidy. If the malignant
transformation results fromrecessive mutations involv-
ing tumor-suppressor genes (69), then it is understand-
able that only diploid cells would potentially give rise
to malignant neoplasms.
Sargent also reported that hepatocytes derived from
AHF resulting from a protocol showing a high degree
of toxicity and carcinoma incidence, the Solt-Farber
protocol (70), exhibited a high degree of aneuploidy, in
contrast to AHF from the livers of rats subjected to a
relatively mild, nontoxic protocol described by Peraino
et al. (71). We have extended these investigations to a
comparison of karyotypes of GGT+ hepatocytes from
rats subjected only to initiation and promotion (36) with
those from rats on the IPI protocol.
When GGT+ hepatocytes are isolated from an IPI
protocol and compared with those of the initiation-pro-
motion component (Peraino protocol), the results seen
in Table 3 may be obtained. In this case, the distinctive
karyotypes seen in the two protocols can be noted. He-
patocytes isolated from livers subjected to the IPI pro-
tocol exhibit a large proportion of distinctive abnor-
malities and aneuploidy, whereas those from the
initiation-promotion protocol exhibit essentially none
(not different from control values). By a study ofthese
two protocols in which the stage of progression can be
delineated, one may investigate any specific karyotypic
abnormalities that may be seen to result from admin-
istration of the progressor agent. As yet, no specific
pattern has been noted as to these karyotypic abnor-
malities. However, other biological changes are noted
in AHF in the stage ofprogression, some ofwhich will
now be considered.
Altered Proto-Oncogene Expression during
Multistage Hepatocarcinogenesis
Although the quantitation offoci-in-foci or promoter-
independent AHF may give some quantitative indica-
tions of the stage of progression, it is still clear that
there aremuchgreaternumbers ofeitherofthesetypes
of lesions than of hepatocellular carcinomas, which ap-
pear later. In attempts to delineate possible abnormal-
ities in gene expression that could better predict those
AHF which are direct precursors of carcinomas, we
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have investigated the expression of several proto-onc-
ogenes during the stages ofpromotion and progression.
In an earlier publication (72), an increased expression
of c-Ha-ras and c-myc occurred in some, but not all,
hepatocellular carcinomas. However, no increased ex-
pression ofthese proto-oncogenes was noted in cells of
AHF during the stage ofpromotion (72,73). In prelim-
inary experiments with immunohistochemical tech-
niques, there was essentially no change in the amount
of protein products for these genes, as well as for the
c-rafproto-oncogene product.
Other workers, however, have demonstrated in-
creased expressions ofthe c-Ha-rafand c-myc genes in
primary hepatomas induced by the continuous feeding
of 3'-methyl-4-dimethylaminobenzene (74,75). Sim-
ilarly, AHF, nodules, and malignancies ofthe liver re-
sulted from protocols in which a necrogenic dose of in-
itiating agent exhibited increased levels of these two
proto-oncogene products (76,77), as well as that of the
c-src proto-oncogene (78). We have, therefore, searched
for increased expression ofthese proto-oncogenes early
during the stage of progression and have occasionally
seen such expression, but as yet we have not been able
to devise techniques for its quantitation. It is possible,
however, that those rare foci-in-foci in which the sec-
ondary focus shows an increased expression of one or
more proto-oncogenes may be related to an aneuploid
karyotype and the ultimate hepatocellular carcinomas.
Conclusions
Although model biological systems cannot completely
replicate all possible variations seen in the varieties of
systems studied, as well as in the human, experimental
findings in model systems can be used as a basis for
studies and points ofcorrelation and explanation ofepi-
demiologic and pathologic observations on human can-
cer. Multistage hepatocarcinogenesis in the rat offers
many advantages in relation to actual or potential
quantitation of the stages ofinitiation, promotion, and
progression, as well as identification of carcinogenic
agents that act primarily at one or another of these
stages rather than all three. Critical in the use of this
and other model multistage carcinogenesis systems in
solid organs is the ability to quantitate the earliest le-
sionsafterinitialadministration ofthecarcinogen. Stud-
ies of the molecular markers that allow identification
and quantification of such lesions are critical to the op-
erational experimentation involved. However, the dem-
onstration ofthedifferential expression ofspecificgenes
compared with normal hepatocytes probably effects ab-
normalities in cellular function that are directly or in-
directly related to the mechanisms of the neoplastic
transformation. Although no ubiquitous marker has
been found that characterizes any of the stages in car-
cinogenesis, it is now reasonable to argue that the in-
crease or lack of expression of specific genes in trans-
formed celis is directly related to their expression of
the malignant phenotype. Since studies thus far have
been characterized by an extreme variation in marker
expression, it is likely that there are multiple pheno-
types and genotypes that can lead to or are character-
istic ofthe malignant cell.
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